

2014 年

英文論文

1, Treatment of acute uncomplicated cystitis with faropenem for 3 days versus 7 days: multicentre, randomized, open-label, controlled trial.

Hamasuna R, Tanaka K, Hayami H, Yasuda M, Takahashi S, Kobayashi K, Kiyota H, Yamamoto S, Arakawa S, Matsumoto T; Japanese Research Group for UTI (JRGU).
J Antimicrob Chemother. 269(6):1675-80, 2014.

2, Clinical effectiveness and safety of tazobactam/piperacillin 4.5 g for the prevention of febrile infectious complication after prostate biopsy.

Yasuda M, Nakane K, Yamada Y, Matsumoto M, Sho T, Matsumoto M, Kobayashi K, Shigemura K, Nakano Y, Tanaka K, Hamasuna R, Ishihara S, Arakawa S, Yamamoto S, Matsubara A, Fujisawa M, Deguchi T, Matsumoto T.
J Infect Chemother. 20(10):631-4, 2014.

3, Nationwide survey of urogenital tuberculosis in Japan.

Nakane K, Yasuda M, Deguchi T, Takahashi S, Tanaka K, Hayami H, Hamasuna R, Yamamoto S, Arakawa S, Matsumoto T.
Int J Urol. 21(11):1171-7, 2014.

4, SLCO1B1, SLCO2B1, and SLCO1B3 polymorphisms and susceptibility to bladder cancer risk.

Bui HT, Fujimoto N, Kubo T, Inatomi H, Matsumoto T.
Cancer Invest. 32(6):256-61, 2014.

5, Occurrence of infection following prostate biopsy procedures in Japan: Japanese Research Group for Urinary Tract Infection (JRGU) - a multi-center retrospective study.

Togo Y, Kubo T, Taoka R, Hiyama Y, Uehara T, Hashimoto J, Kurimura Y, Takahashi S, Tsukamoto T, Miyazaki J, Nishiyama H, Kira S, Kiyota H, Yazawa S, Niwa N, Hongo H, Oya M, Kato T, Yasuda M, Deguchi T, Ishikawa K, Hoshinaga K, Matsumoto M, Shigemura K, Tanaka K, Arakawa S, Fujisawa M, Wada K, Uehara S, Watanabe T, Kumon H, Kobayashi K, Matsubara A, Matsumoto M, Sho T, Hamasuna R, Matsumoto

T, Hayami H, Nakagawa M, Yamamoto S.

J Infect Chemother. 20(4):232-7, 2014.